Urinary melatonin levels, sleep disruption, and risk of prostate cancer in elderly men.
Name:
Publisher version
View Source
Access full-text PDFOpen Access
View Source
Check access options
Check access options
Average rating
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Star rating
Your vote was cast
Thank you for your feedback
Thank you for your feedback
Authors
Sigurdardottir, Lara GMarkt, Sarah C
Rider, Jennifer R
Haneuse, Sebastien
Fall, Katja
Schernhammer, Eva S
Tamimi, Rulla M
Flynn-Evans, Erin
Batista, Julie L
Launer, Lenore
Harris, Tamara
Aspelund, Thor
Stampfer, Meir J
Gudnason, Vilmundur
Czeisler, Charles A
Lockley, Steven W
Valdimarsdottir, Unnur A
Mucci, Lorelei A
Issue Date
2015-02
Metadata
Show full item recordCitation
Eur. Urol. 2015, 67 (2):191-4Abstract
Melatonin has anticarcinogenic properties in experimental models. We undertook a case-cohort study of 928 Icelandic men without prostate cancer (PCa) nested within the Age, Gene/Environment Susceptibility (AGES)-Reykjavik cohort to investigate the prospective association between first morning-void urinary 6-sulfatoxymelatonin (aMT6s) levels and the subsequent risk for PCa, under the hypothesis that men with lower aMT6s levels have an increased risk for advanced PCa. We used weighted Cox proportional hazards models to assess the association between first morning-void aMT6s levels and PCa risk, adjusting for potential confounders. A total of 111 men were diagnosed with incident PCa, including 24 with advanced disease. Men who reported sleep problems at baseline had lower morning aMT6s levels compared with those who reported no sleep problems. Men with morning aMT6s levels below the median had a fourfold statistically significant increased risk for advanced disease compared with men with levels above the median (hazard ratio: 4.04; 95% confidence interval, 1.26-12.98). These results require replication in larger prospective studies with longer follow-up.In this report, we evaluated the prospective association between urinary aMT6s levels and risk of PCa in an Icelandic population. We found that lower levels of aMT6s were associated with an increased risk for advanced PCa.
Description
To access publisher's full text version of this article, please click on the hyperlink in Additional Links field or click on the hyperlink at the top of the page marked Files. This article is open access.Additional Links
http://dx.doi.org/ 10.1016/j.eururo.2014.07.008http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4318783/
Rights
Archived with thanks to European urologyae974a485f413a2113503eed53cd6c53
10.1016/j.eururo.2014.07.008
Scopus Count
Collections
Related articles
- Association of Urinary 6-Sulfatoxymelatonin (aMT6s) Levels and Objective and Subjective Sleep Measures in Older Men: The MrOS Sleep Study.
- Authors: Saksvik-Lehouillier I, Harrison SL, Marshall LM, Tranah GJ, Ensrud K, Ancoli-Israel S, Clemons A, Redline S, Stone KL, Schernhammer ES, Osteoporotic Fractures in Men (MrOS) Study Group.
- Issue date: 2015 Dec
- Association of urinary levels of 6-sulfatoxymelatonin (aMT6s) with prevalent and incident hypertension.
- Authors: Pérez-Caraballo AM, Ma Y, Ockene JK, Reeves KW, Balasubramanian R, Stanczyk FZ, Allison MA, Chen C, Wang L, Manson JE, Sturgeon SR
- Issue date: 2018 Aug
- Disruption of sleep, sleep-wake activity rhythm, and nocturnal melatonin production in breast cancer patients undergoing adjuvant chemotherapy: prospective cohort study.
- Authors: Li W, Kwok CC, Chan DC, Ho AW, Ho CS, Zhang J, Wing YK, Wang F, Tse LA
- Issue date: 2019 Mar
- Exploratory assessment of pineal gland volume, composition, and urinary 6-sulfatoxymelatonin levels on prostate cancer risk.
- Authors: Bazzi LA, Sigurdardottir LG, Sigurdsson S, Valdimarsdottir U, Torfadottir J, Aspelund T, Czeisler CA, Lockley SW, Jonsson E, Launer L, Harris T, Gudnason V, Mucci LA, Markt SC
- Issue date: 2021 Jun
- Sleep disruption among older men and risk of prostate cancer.
- Authors: Sigurdardottir LG, Valdimarsdottir UA, Mucci LA, Fall K, Rider JR, Schernhammer E, Czeisler CA, Launer L, Harris T, Stampfer MJ, Gudnason V, Lockley SW
- Issue date: 2013 May